Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu


Welcome to the Multiple Sclerosis Discovery Forum

An online community and information portal that aims to inspire connections and clinical advances



Become a Member

News & Future Directions

News Briefs | 29 Sep 2014

159 Genetic Variants Now Known to Be Associated With MS

The International MS Genetics consortium recently identified more than 45 new genetic variants associated with susceptibility to multiple sclerosis, many of which are involved in brain function

The list of genetic variants associated with multiple sclerosis grew even longer earlier this year at the...
News Briefs | 29 Sep 2014

MS Research Roundup: September 29, 2014

Undiagnosed Sleep Disorders in MS; False Hits Foil Drug Discovery; Myelin Through the Ages; Yoga for MS; Neuroscience Ig Nobel Prize

Items of interest to multiple sclerosis researchers from around the Web...
News Synthesis | 26 Sep 2014

What’s the Role of Myelin Oligodendrocyte Glycoprotein in NMO?

Researchers are working to refine a cell-based assay that more accurately identifies antibodies for myelin oligodendrocyte glycoprotein (MOG) in the serum of patients with neuromyelitis optica spectrum disorders. Some think that anti-MOG-positive patients may even represent a distinct demyelinating disease.

Scientists understand neuromyelitis optica spectrum disorders far better now than when they were...
News Synthesis | 24 Sep 2014

The Paradox of Daclizumab

Phase 3 results show that daclizumab reduces disease activity in relapsing-remitting multiple sclerosis by half compared with interferon, as measured by brain imaging, with skin and other side effects. The drug works in surprising ways that are revealing new details about the pathogenesis of MS.

Three might be the lucky number for daclizumab, an investigational drug for relapsing-remitting multiple sclerosis with...

Research Resources

Tools that will help investigators conceive and perform experimental work:

  • The Data Visualization section presents MS-related data in new ways, making it easy for viewers to discover unexpected relationships
    Our latest visualization is a force-directed graph presenting the connections among the 250 authors who published articles in the scientific literature between April 1993 and June 2014 concerning phase 3 clinical trials in multiple sclerosis.

  • Drug-Development Pipeline consolidates key information about compounds under investigation for therapeutic use
    We've updated information on four trials and added four other pieces of information. The drugs with important additions and changes are fingolimod, interferon β-1a, and natalizumab. We also added a new entry for MIS416, which contains information on two trials as well as 50 other pieces of information.
  • Tissue Repositories lists features of the world's tissue repositories and brain banks, including rules of engagement and contact information
  • MSGene provides a comprehensive, unbiased and regularly updated collection of genetic association studies performed on multiple sclerosis phenotypes
  • Animal Models summarizes the promises and pitfalls of animal models used in MS research
    We added a detailed review of the cuprizone mouse model of MS.

  • Clinical Trials lists sources of information about MS clinical trials

Professional Resources

Papers of the Week


Discussions | 22 Oct 2013

Evoked potential test

I'm interested in everything related to Evoked Potential  testing

Recent Comments

News Briefs | 30 Sep 2014
As usual, the International MS Genetics...
Discussions | 12 Sep 2014
You are right, I did forget to mention that....
Discussions | 11 Sep 2014
Thanks for the reply. I think I found the nuance...

MSDF Tweets

NYAS T Cell Meeting

In the News
Read Science Translational Medicine's article about MS Discovery Forum